Angel Scale Biotech: Learn More

Tomer Amit and Sonia Berrih-Aknin, PhD founded PreciseMent Health to target treatments for depression and bipolar disorder guided by protein markers associated with good outcomes. The work promises to address the great uncertainties that exist in current treatment practices. Truly a mind-expanding conversation with a compelling team.

Sponsored by Purdue University entrepreneurship and Peter Fasse, patent attorney at Fish and Richardson.

Highlights:

• Sal Daher Introduces Tomer Amit and Sonia Berrih-Aknin, PhD
• What PreciseMent Health is Solving
• "...Basically, you had a database of patient data, where the patient's response to treatment had been recorded. Then you took blood samples, and you analyzed to see if there were proteins that indicated certain treatments being more likely to lead to successful treatment than others..."
• "... Really, for the first time, we can say that we are identifying dependable biosignatures in the peripheral blood..."
• Dealing With Side Effects
• "... We'll make it more accessible because of the copay. The $2,000 has a $300 copay with it, which makes it very difficult for a lot of people to pay. We can go in a lot lower because our costs of goods sold are going to be lower ... We want to really have a huge change in the way that mental health is treated and diagnosed..."
• Intellectual Property Protection
• "...We're targeting initially the psychiatry market. We'll be looking to provide them with a plasma card test, which will give them, in a sense, for the first time, the ability to test an individual at the point of care with a few drops of blood..."
• Tomer and Sonia's Backstories
• "... we are in the process of having biotechnology eat the world as software was eating the world for the last 11 years. We're seeing everything being turned over and reinterpreted in the light of these extremely powerful technologies that can discover patterns, where, before, it was just invisible for us..."

Topics: biotech, co-founders, founding stories